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OBJECTIVE—To compare the prevalence of prediabetes using A1C, fasting plasma glucose
(FPG), and oral glucose tolerance test (OGTT) criteria, and to examine the degree of agreement
between the measures.
RESEARCH DESIGN AND METHODS—We used the 2005–2008 National Health and
Nutrition Examination Surveys to classify3,627adults aged $18 years without diabetes accord-
ing to their prediabetes status using A1C, FPG, and OGTT. We compared the prevalence of
prediabetesaccordingtodifferentmeasuresandusedconditionalprobabilitiestoexamineagree-
ment between measures.
RESULTS—In 2005–2008, the crude prevalence of prediabetes in adults aged $18 years was
14.2% for A1C 5.7–6.4% (A1C5.7), 26.2% for FPG 100–125 mg/dL (IFG100), 7.0% for FPG
110–125 mg/dL (IFG110), and 13.7% for OGTT 140–199 mg/dL (IGT). Prediabetes prevalence
variedby age,sex, and race/ethnicity,andthere was considerablediscordancebetweenmeasures
ofprediabetes.AmongthosewithIGT,58.2,23.4,and32.3%hadIFG100,IFG110,andA1C5.7,
respectively, and 67.1% had the combination of either A1C5.7 or IFG100.
CONCLUSIONS—The prevalence of prediabetes varied by the indicator used to measure
risk;therewasconsiderablediscordancebetweenindicatorsandthecharacteristicsofindividuals
with prediabetes. Programs to prevent diabetes may need to consider issues of equity, resources,
need, and efﬁciency in targeting their efforts.
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ncreased levels of glycemia in the pre-
diabetic range, measured by fasting or
postchallenge glucose or by A1C can
serve as simple and reasonably accurate
predictors of subsequent type 2 diabetes
risk (1). Aboveand beyonditsassociation
with diabetes, hyperglycemia at the pre-
diabetic level is associated with increased
risk of subsequent cardiovascular disease
(2–5). The value of glycemic measures is
further strengthened by evidence that di-
abetesriskcanbereducedwithstructured
lifestyle interventions and/or metformin
amongindividualswithlevelsofglycemia
above normal but below the diagnostic
threshold for diabetes (6–8). This means
that measures of glycemia can serve as
practical indicators for referral to diabetes
prevention programs.
As e r i e so fd e ﬁnitions to classify
people at elevated glycemic risk have
been recommended, including impaired
glucose tolerance (IGT), impaired fasting
glucose (IFG), and “prediabetes.” In
1979, the National Diabetes Data Group
(NDDG) deﬁned IGT as fasting plasma
glucose (FPG) ,140 mg/dL and 2-h
plasma glucose values ranging from 140
to 199 mg/dL (9). The World Health Or-
ganization (WHO) also adopted this rec-
ommendation. The term IFG was
introduced in 1997, whereby FPG values
from 110 to 125 mg/dL additionally dif-
ferentiated the metabolic state between
normal and diabetic (10). In 2003, the
Expert Committee on the Diagnosis and
Classiﬁcation of Diabetes Mellitus (11)
lowered the FPG cut point for IFG to
100 mg/dL, which optimized sensitivity
and speciﬁcity in predicting diabetes
and made the prevalence of prediabetes
more comparable to IGT prevalence.
The WHO did not change its previous
recommendations, placing greater em-
phasis on 2-h plasma glucose.
Most recently, the American Diabetes
Association recommended an A1C range of
5.7–6.4%toidentifyindividualsathighrisk
forfuturediabetes(1).Becauseanovernight
fast is not required to measure A1C, this
changeisexpectedtofacilitateidentiﬁcation
of people at risk for diabetes who could
beneﬁt from intervention.
Each change in deﬁnition has impli-
cations for the population prevalence of
prediabetes, along with potential devo-
tion of resources. Thus, we examined
nationally representative data to 1)d e -
scribe the prevalence of prediabetes
among the U.S. population according to
different glycemic measures and combi-
nations of measures and 2) examine the
degree of agreement between measures.
RESEARCH DESIGN AND
METHODS—The 2005–2008 National
Health and Nutrition Examination Survey
(NHANES)wasconductedbytheNational
Center for Health Statistics (NCHS), Cen-
ters for Disease Control and Prevention
(12,13). NHANES uses a complex, multi-
stage probability sample design to collect
datarepresentativeoftheU.S.civiliannon-
institutionalizedpopulation.Surveypartic-
ipants are interviewed at home and invited
to attend a mobile examination center to
undergomedicalexaminations and labora-
tory measurements. Among participants
aged18yearsandolder,11,791completed
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pleted the examination.
During the home interview, partici-
pants were asked if they have ever been
told by a doctor or other health profes-
sional that they had diabetes (other than
during pregnancy). On the basis of this
question, 1,272 respondents aged 18 years
and older were classiﬁed as having diag-
nosed diabetes.
Survey participants were randomly
assignedtoeitheramorningorafternoon/
evening examination session: 4,881 indi-
viduals aged 18 years and older without
diagnosed diabetes were examined
duringamorningsession.Afterexcluding
people who fasted ,8o r$24h (n =586)
and individuals with invalid FPG values
(n = 118), the FPG subsample comprised
4,177 adults. An oral glucose tolerance
test (OGTT) 2-h (6 15 min) measure-
ment was obtained for 3639 (87%) of
those in the FPG subsample. Participants
withintheOGTTsubsamplewithmissing
A1C values (n = 12) were excluded re-
sulting in a subsample of 3,627 adults.
As a result of changes in laboratory
equipment,aDemingregressionequation
(Y = X 2 1.139) was applied to FPG and
OGTT values to make 2007–2008 data
comparable to 2005–2006 data. A glucose
regression equation (Y = 0.9835 3 X)
was applied to FPG and OGTT values,
and a Deming regression equation (Y =
0.4892 + 0.9277 3 X) was applied to
A1C values to make 2005–2008 data
comparable to previous years (13). A1C
data were reanalyzed without the correc-
tionandnosigniﬁcantdifferenceinresults
was observed.
Individuals without self-reported dia-
beteswereclassiﬁedashavingundiagnosed
diabetes if any of the following thresh-
olds were exceeded: FPG $126 mg/dL,
A1C $6.5%, or OGTT $200 (n = 276).
For those without diabetes, prediabetes
was deﬁned according to different glyce-
micriskstrata:A1C5.7–,6.5%(A1C5.7);
FPG 100–,126 mg/dL (IFG100); OGTT
140–,200 mg/dL (IGT); FPG 110–,126
mg/dL (IFG110); A1C5.7 or IFG100
(A1C5.7-IFG100); A1C5.7 or IGT
(A1C5.7-IGT); A1C5.7 or IFG110
(A1C5.7-IFG110). (Estimates for predi-
abetes as deﬁned by IGT or IFG100 and
by IGT or IFG110 are available in
Supplementary Table 1.)
For NHANES 2005–2008, individu-
als with diagnosed diabetes from the in-
t e r v i e w e ds a m p l ew e r ec o m b i n e dw i t h
individuals without diagnosed diabetes
from the OGTT subsample. Interview
and OGTT subsample weights (provided
by NCHS) were used so that the sum of
the sample weights from the two subsam-
ples summed to the total U.S. noninstitu-
tionalized population. We standardized
estimates to the U.S. 2000 Census popu-
lation using three age groups (i.e., 18–44,
45–64, $65 years). We used SAS 9.2 for
Windows software (SAS Institute, Cary,
NC) for data management and SUDAAN
10 software (Research Triangle Institute,
Research Triangle Park, NC) to obtain
point estimates and SEs, using the Taylor
series linearization method.
One-sample Student t tests were used
for testing whether differences between
subgroups were signiﬁcantly different
from zero. A P value of ,0.05 was consid-
ered statistically signiﬁcant. Conditional
probabilities were calculated to measure
agreement.
RESULTS
Prevalences in 2005–2008
The crude prevalences and 95% CIs of
prediabetes among U.S. adults aged $18
years(Table1)were14.2%(12.8–15.6)for
A1C5.7, 26.2% (24.2–28.2) for IFG100,
13.7% (12.1–15.3) for IGT, and 7.0%
(6.0–8.0) for IFG110. When the measures
were combined todeﬁne prediabetes, the
prevalences were 32.2% (30.4–34.0) for
A1C5.7-IFG100, 23.5% (22.1–24.9) for
A1C5.7-IGT, and 18.1% (16.8–19.4)
forA1C5.7-IFG110.Forthecombination
of all three measures—IFG100, A1C5.7,
or IGT—prevalence was 36.7% (34.8–
38.6).
Prevalence by age
Across the three age groups, prediabetes
prevalence was lowest for IFG110 and
highestforIFG100,withA1C5.7andIGT
falling in between (Table 1). Prevalence
increased with age for most measures.
Table 1—Crude and age-adjusted prevalence of prediabetes in adults aged ‡18 years, by prediabetes indicator, NHANES 2005–2008
A1C5.7 IFG100 IGT IFG110 A1C5.7 or IFG100 A1C5.7 or IGT A15.7 or IFG110
n 696 1,074 597 303 1,395 1,069 856
Crude
Total 14.2 (0.7) 26.2 (1.0) 13.7 (0.8) 7.0 (0.5) 32.2 (0.9) 23.5 (0.7) 18.1 (0.7)
18–44 (years) 6.7 (0.6) 18.8 (1.2) 8.4 (0.8) 4.3 (0.6) 22.0 (1.1) 13.7 (0.9) 9.7 (0.6)
45–64 (years) 19.3 (1.6) 34.0 (2.3) 15.5 (1.5) 8.9 (1.0) 41.0 (2.3) 29.3 (1.5) 24.0 (1.7)
65+ (years) 25.6 (2.3) 31.6 (1.5) 25.9 (1.9) 10.6 (1.4) 43.6 (2.1) 40.3 (2.1) 30.6 (2.2)
Male 14.3 (0.9) 33.1 (1.5) 12.8 (0.9) 8.8 (0.8) 37.9 (1.6) 23.1 (1.0) 19.7 (1.0)
Female 14.1 (1.1) 19.7 (1.1) 14.6 (1.1) 5.2 (0.6) 26.8 (1.0) 24.0 (1.1) 16.7 (0.9)
NH white 12.9 (1.0) 27.1 (1.3) 14.5 (1.1) 7.5 (0.7) 32.1 (1.4) 22.9 (1.2) 17.3 (1.0)
NH black 24.8 (1.6) 17.9 (1.4) 7.3 (0.8) 3.7 (0.8) 33.6 (1.7) 28.0 (1.5) 26.1 (1.8)
Mex-Am 13.2 (1.3) 28.3 (2.2) 15.1 (1.5) 7.1 (1.1) 33.9 (1.9) 24.0 (2.1) 17.3 (1.4)
Age-adjusted*
Total 13.7 (0.6) 25.5 (0.9) 13.5 (0.7) 6.8 (0.5) 31.4 (0.8) 22.9 (0.6) 17.5 (0.5)
Male 14.0 (0.7) 32.3 (1.4) 12.8 (0.8) 8.7 (0.7) 37.1 (1.4) 22.7 (0.7) 19.2 (0.8)
Female 13.3 (1.0) 19.1 (1.1) 14.2 (1.0) 5.1 (0.6) 25.8 (1.0) 23.0 (1.1) 15.9 (0.9)
NH white 11.6 (0.8) 25.5 (1.2) 13.6 (0.9) 7.0 (0.6) 30.0 (1.3) 21.1 (0.9) 15.8 (0.8)
NH black 24.4 (1.6) 17.3 (1.3) 7.4 (0.8) 3.5 (0.7) 33.0 (1.7) 27.8 (1.5) 25.6 (1.8)
Mex-Am 14.6 (1.3) 27.5 (2.1) 16.1 (1.3) 7.5 (1.1) 34.0 (1.8) 25.9 (1.7) 19.0 (1.4)
Data are percent based on weighted data (SE). Estimates are based on the morning OGTT subsample. Diagnosed and undiagnosed diabetes estimates not shown.
Includes racial/ethnic groups not shown separately. *Standardized to the 2000 U.S. Census population by age using three age groups (18–44, 45–64, $65 years).
Mex-Am, Mexican American; NH, non-Hispanic; n, unweighted number.
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Alternative deﬁnitions of prediabetesHowever, the age-related gradient was
notably steeper for IGT and A1C5.7
than for the IFG100 measure. For ex-
ample, when deﬁned by A1C5.7, IGT,
A1C5.7-IGT combination, or the A1C5.7-
IFG110 combination, prevalence was ap-
proximately three times as high among
those $65 years of age as among those
18–44 years of age. However, when pre-
diabetes was deﬁned by IFG100 or
the A1C5.7-IFG100 combination, older
adults had only twice the prevalence, and
therewasnosigniﬁcantdifferencebetween
middle-aged and older adults.
Prevalence by sex
Age-adjusted prevalence as measured by
A1C5.7 or IGT did not vary signiﬁcantly
between men and women (P =0 . 8 7a n d
P = 0.14, respectively) (Table 1). How-
ever, men were much more likely than
women to have IFG100 (P , 0.01) and
IFG110 (P , 0.01). Though diminished,
this sex difference was also evident when
IFG was combined with other indicators
(A1C5.7-IFG100, P , 0.01; A1C5.7-
IFG110, P , 0.01). Prevalence did not
vary signiﬁcantly by sex when measured
by the A1C5.7-IGT combination (P =
0.56).
Prevalence by race/ethnicity
The relationship between race/ethnicity
and prediabetes prevalence varied ac-
cording to the indicator used to measure
prediabetes (Table 1). When A1C5.7 was
used, age-adjusted prevalence among
non-Hispanic blacks was almost twice
that of non-Hispanic whites and Mexican
Americans (allP,0.01).However,when
IFGandIGTwereusedasmeasures,prev-
alence among non-Hispanic whites and
Mexican Americans was about twice that
of non-Hispanic blacks (all P , 0.05).
Prevalence was similar across race/
ethnicity groups when deﬁned using the
A1C5.7-IFG100 combination, but higher
among non-Hispanic blacks when the
A1C5.7-IGT and the A1C5.7-IFG110
combinations were used. Regardless of
the measure used, prediabetes prevalence
was similar between non-Hispanic whites
and Mexican-Americans.
Agreement
Only 3.2% (95% CI 2.3–4.0) of adults
had all three indicators (i.e., IFG100,
A1C, and IGT), and an additional 11.2%
(9.8–12.5)hadtwoofthethreeindicators
(Table 2 and Supplementary Fig. 1). The
prevalence of those positive for only one
of the three indicators was 22.4% (20.7–
24.1); with IFG100 only (prevalence
13.2% [95% CI 11.7–14.6]) accounting
for the majority. The prevalence of pos-
sessing only one indicator varied by de-
mographic factors. The prevalence of
IFG100 only was twice as large in men
(17.9% [15.5–20.4]) than in women
(8.7 [6.9–10.4]) and A1C5.7 only was
three times larger among non-Hispanic
blacks (13.8% [11.4–16.2]) than among
non-Hispanic whites (3.8% [2.9–4.7]) and
Mexican-Americans (3.9% [2.3–5.4]).
Among adults with IFG100, 30.6%
had IGT and 31.6% had prediabetes,
based on A1C5.7 (Table 3). Among those
with prediabetes based on A1C5.7, 57.9,
21.3, and 31.1% had prediabetes based
on IFG100, IFG110, and IGT, respec-
tively. Among those with IGT, 58.2,
23.4, and 32.3% have IFG100, IFG110,
and A1C5.7, respectively, and 67.1% had
the A1C5.7-IFG100 combination.
CONCLUSIONS—In a representative
sample of the U.S. adult population, the
prevalenceofthoseathighriskofdiabetes
varied greatly by the indicator used to
measure risk. For example, the prevalence
of prediabetes as measured by IFG100
(26.2%) was almost twice that measured
by A1C5.7 (14.2%) and IGT (13.7%) and
over three times that of IFG110 (7.0%).
The combination of either A1C5.7 or
IFG100 resulted in a prevalence of almost
33%. Thus, if these indicators are used to
identify the number of individuals eligible
for prevention efforts, the number of
individualswouldrangefrom15.3million
(7% with IFG110) to 70.9 million (32.2%
with A1C5.7-IFG100). If all three mea-
sures are combined, the number of indi-
viduals at high risk of diabetes would be
80.8 million (36.7% with A1C5.7,
IFG100 or IGT).
Our study suggests that the speciﬁc
choice of a prediabetes measure will yield
differing associations with age, sex, and
race. Although the prevalence of A1C5.7
and IGT was similar for men and women,
IFG100 or IFG110 was about 1.7 times
higher among men than women. These
sex differences in prevalence are consis-
tent with the ﬁndings of several interna-
tional studies. Summarizing data from 13
European and 10 Asian studies, the writ-
ing committee for the International Di-
abetes Federation IGT/IFG consensus
statement (14) found IFG110 to be con-
sistently more common in men than
women, typically 1.5–3t i m e sh i g h e r .A l -
thoughthereasonsforthissexdifferential
are unknown, some have suggested that
theunderlyingetiologiesormetabolicde-
terminants of FPG and OGTT values may
differ (14,15). Further, analysis of the Di-
abetes Prevention Program data suggested
that progression to diabetes was more de-
pendent upon FPG in men, whereas pro-
gression in women was more dependent
on OGTT (16). Regardless of the reasons
for the sex differences in IFG prevalence,
epidemiological research and prevention
programs solely using IFG to determine
prediabetes status will identify a prepon-
derance of men. For every 100 people
eligible for enrollment in prevention pro-
grams based on IFG, about 63 would be
men and 37 would be women.
In our study, prediabetes prevalence
measuredbyA1C5.7wasabouttwotimes
higher in non-Hispanic blacks than in
non-Hispanic whites and Mexican Amer-
icans, but was only half that of non-
Hispanic whites and Mexican Americans
when measured by IGT or IFG110. Prior
research comparing A1C and FPG and/
or OGTT prediabetes deﬁnitions noted
ethnic differences in prevalence and sug-
gested changes to diagnostic criteria of
diabetes or prediabetes may lead to sub-
stantial changes in prevalence among dif-
ferent ethnic groups (14,17–22). Some
Table 2—Prevalence of prediabetes in adults aged ‡18 years, by prediabetes indicator,
NHANES 2005–2008
IFG100 A1C5.7 IGT Total Men Women NH white NH black Mex-Am
All 3 Positive + + + 3.2 3.1 3.2 3.4 2.2 2.5
2 Positive
++ 2 5.1 6.4 3.8 4.6 6.9 5.1
+ 2 + 4.8 5.6 4.1 5.4 1.3 5.8
2 + + 1.3 0.9 1.6 1.2 2.0 1.7
1 Positive
+ 22 13.2 17.9 8.7 13.8 7.6 14.9
2 + 2 4.7 3.9 5.5 3.8 13.8 3.9
22 + 4.5 3.1 5.8 4.8 1.9 5.0
Data are percent unless otherwise indicated. Mex-Am, Mexican American; NH, non-Hispanic.
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James and Associateswarned that using A1C alone to screen for
type-2 diabetes risks misdiagnosing large
numbers of patients, especially those of
African, Mediterranean, or south-east
Asian heritage (23,24) and/or may be par-
ticularly insensitive in diagnosing whites
(19–21). Further, studies have raised the
concern that the relationship between
A1C and other glycemic markers differs
by race and ethnicity (21,22,25). For ex-
ample, compared with their Caucasian
counterparts, African Americans in partic-
ular have higher A1C levels at any given
level of FPG. This may be inﬂuenced in
part by genetic traits inﬂuencing erythro-
cyte turnover, or alternatively, by nutri-
tional or metabolic factors. Whether this
v a r i a t i o ni nt h er e l a t i o n s h i pa m o n gd i f -
ferent glycemic markers affects predic-
tion of morbid outcomes or whether the
beneﬁt that can be expected from inter-
ventions is strong enough to warrant
ethnic-speciﬁc disease thresholds is not
yet clear. However, a recent analysis of
prospective cohort data from the Athero-
sclerosis Risk in Communities study did
not support the use of race-speciﬁcc u t
points in A1C for identifying individuals
at risk for diabetes (5).
In NHANES, limited data were avail-
able for some race/ethnic groups at high
risk for diabetes, such as Native Ameri-
cans. However, the major strengths of
this study are the nationally representa-
tive data and the inclusion of standard-
ized laboratory, clinical, and physical
measurements.
Our ﬁndings conﬁrm prior observa-
tions that considerable discordance be-
tween A1C, IFG, and IGT exists, and that
the characteristics of individuals identi-
ﬁed at risk for diabetes vary by risk
indicator. This has implications for pre-
ventionprogramsconcerningwhowillbe
identiﬁed and enrolled in prevention
efforts. A1C5.7 may disproportionately
identify non-Hispanic blacks, while IFG
may disproportionately identify men.
D u et ot h el a c ko fag o l ds t a n d a r df o r
comparison, it is unknown whether these
measures are biased or whether these
groups are actually at a higher or lower
risk of developing type 2 diabetes. The
use of a combination of either A1C5.7or
IFG100 approximately equalizes preva-
lence by race/ethnicity, somewhat lessens
sexdifferences,andidentiﬁesthemajority
with IGT (upon whom the prevention
trials were based). However, using this
combination identiﬁes nearly a third of
the U.S. population as at risk for devel-
oping diabetes. Because within each risk
indicator the risk of diabetes increases
across a continuum (6,7), it could be ar-
gued that intervention resources should
be targeted toward those at greatest risk.
Programstopreventdiabetesmayneedto
considerissuesofequity,resources,need,
and efﬁciency in targeting their efforts.
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